Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions

Jiko Yamada1, Hirofumi Tomiyama, Chisa Matsumoto

  • 1Second Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Tokyo 160-0023, Japan.

Insights

Azelnidipine improved autonomic function more than benidipine in hypertensive patients, though both drugs similarly lowered blood pressure. This enhanced autonomic effect did not translate to differences in vascular stiffness or endothelial function.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Autonomic dysfunction is linked to cardiovascular disease.
  • Calcium channel blockers (CCBs) are widely used for hypertension.
  • Investigating differential effects of CCBs on autonomic and vascular function is crucial.

Purpose of the Study:

  • To compare the effects of azelnidipine and benidipine on autonomic functions in hypertensive patients.
  • To determine if azelnidipine's potential benefits on autonomic function impact vascular parameters.
  • To assess changes in arterial stiffness and endothelial function.

Main Methods:

  • Cross-over study in 21 hypertensive patients.
  • Patients received either azelnidipine (16 mg/day) or benidipine (4 mg/day) alternately for 8 weeks.
  • Evaluated heart rate variability, baroreceptor sensitivity (BRS), brachial-ankle pulse wave velocity (baPWV), and flow-mediated vasodilatation (FMD).

Main Results:

  • Both drugs similarly reduced blood pressure.
  • Azelnidipine significantly improved BRS and high-frequency heart rate variability compared to benidipine.
  • No significant differences were observed in baPWV, FMD, or specific biomarkers between the two treatments.

Conclusions:

  • Azelnidipine demonstrates superior benefits for autonomic function compared to benidipine.
  • Despite improved autonomic function, azelnidipine did not show distinct advantages in arterial stiffness or endothelial function over benidipine.
  • These findings suggest a dissociation between autonomic and vascular benefits of these CCBs.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...